Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who have been diagnosed with an incurable, spreading (metastatic) solid tumour (not including primary brain tumours), multiple myeloma, or certain types of B cell non-Hodgkin lymphoma, where no standard life-extending treatment is available or the person has chosen not to have such treatment.
• People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale called ECOG (scores 0, 1, or 2 — meaning fully active to capable of limited self-care).
• People whose blood counts, liver function, and kidney function all fall within the required ranges as determined by blood tests (confirm specific values with the trial site).
• People whose cancer can be measured on scans or tests, so that any changes can be tracked during the trial.
• People whose tumour has been tested for genetic or protein changes (genomic or biomarker testing) through an approved lab or research group listed in the trial protocol, with results showing a potentially targetable change — this testing may have been done on the original tumour, a spread site, bone marrow, or blood.
• People who have provided written consent before the screening step begins, following all relevant local and regulatory rules.
• People who are able to attend treatment and follow-up appointments at a participating trial centre, generally within around 1.5 hours' travelling distance.
• People of childbearing potential who have agreed to use a highly effective method of contraception during the trial.

Who may not be able to join:

• People who have or have had another cancer whose history or treatment could affect how safely or accurately this trial can be assessed.
• People who are still experiencing side effects rated moderate or above (grade 2 or higher on a standard medical scale) from previous cancer treatment — except for certain manageable conditions such as treated low thyroid function; people with severe nerve-related side effects (grade 3 or higher) are also excluded.
• People who are currently receiving any other cancer treatment, including chemotherapy, biological therapy, radiation, or hormonal therapy (other than hormone replacement), with some specific exceptions such as supportive medications that may have some anti-cancer effect (confirm details with the trial site).
• People with brain metastases (cancer that has spread to the brain) that are currently active or getting worse; people with previously treated brain metastases may still be considered, provided the condition has been stable — both in symptoms and on scans — for at least one month, with no seizures or significant neurological changes in that time, and steroid use is at a minimal or nil level.
• People with serious pre-existing heart conditions, such as uncontrolled chest pain (angina), uncontrolled irregular heart rhythms, or symptomatic heart failure.
• People whose heart pumping function (left ventricular ejection fraction) is measured at less than 40%.
• People who have had a stroke, mini-stroke (TIA), or heart attack within the three months before the screening step.
• People who have had significant bleeding from the gastrointestinal tract (digestive system) within one month before the screening step.
• People with other significant medical conditions — such as active infection, severely uncontrolled high blood pressure, or serious psychiatric illness — that in the treating doctor's judgement would make participation unsafe or difficult.
• Women who are currently breastfeeding.
• People who do not meet the additional eligibility requirements specific to the particular drug being considered for them by their treating doctor.

Important: Always verify eligibility with the trial site directly before applying.